Turku, Finland and Laupheim, Germany – January 17th, 2011. Faron Pharmaceuticals Ltd. and Rentschler Biotechnologie GmbH announced today that they have signed a manufacturing and supply agreement for the Faron product FP-1201 that is also known as Traumakine®. The active pharmaceutical ingredient of the FP-1201 is recombinant human interferon beta-1a (IFN-beta 1a) that was first produced by Rentschler already in the late 1980’s. According tothe agreement Rentschler will become the sole global manufacturer of IFN-beta1a for Faron and also manufacture Faron’s proprietary bulk drug product. Traumakine® is formulated so that it is stable at room temperature and readily available for critical care doctors at intensive treatment units. Traumakine® is meant to prevent vascular leakage in patients with acute lung injuries (ALI) and its more severe form ARDS. This prevention is critical to sustain respiratory function in ALI/ARDS patients. Financial details of the agreement were not disclosed.

Download press release